Orion predicted strong growth for darolutamide, the prescription prostate-cancer medication it co-developed with Bayer.

The Bayer Pharma AG logo is seen on April 03, 2025 in Berlin, Germany. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...

July 9 (Reuters) - The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased by an experimental non-hormonal drug being developed by ...

BAYRY jumps 6.6% after partner Orion said Nubeqa sales tied to Bayer could top ???1B long term. Bayer also announced pharma ...

Bayer's drug candidate to ease menopausal hot flashes was deemed safe and effective for long-term use in study results released this week as the German pharma giant awaits delayed approval by U.S.

In early January 2026, Bayer’s subsidiaries and partners reported a series of R&D advances, including FDA acceptance of AskBio’s IND for AB-1009 gene therapy for late-onset Pompe disease with Fast ...

Secondary US filings for Bayer assets cannot be relied on again to face future patent cliffs, demanding focus on early-stage ...

FRANKFURT (Reuters) - Germany's Bayer and its U.S. development partner Onyx have reached a settlement over a contested sister compound to their potential blockbuster cancer drug Nexavar. As part of ...

The U.S. Food And Drug Administration (FDA) granted full approval to Bayer AG’s (OTC:BAYRY) Vitrakvi (larotrectinib) for adult and pediatric patients with solid tumors that have a neurotrophic ...